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ABSTRACT 
Our objective was to determine the risk factors for BK virus infection in renal allograft 
recipients in the first year after transplantation. In this cohort, we included all patients who 
received renal allograft at London Health Sciences Centre (LHSC) between 2012 and 2014. 
We continued post-transplantation follow-up for one year. Of 175 patients (37% female) 
with median age (range) of 53 (14-82) years, 40 (22.9%) developed BK viremia (median 
interval:100 days, range: 35-264). Recipient age, recipient gender, hemodialysis (HD) vs 
peritoneal dialysis (PD), Human Leukocyte Antigens A1, B35 and Cw4 increased the risk of 
post-transplant BKV infection. However, donor gender, donor age, deceased vs living donor, 
delayed graft function, ABO incompatibility and retransplantation did not increase the risk. 
PD and HD patients do not appear to have equal risks at the time of transplantation. Further 
studies are required to determine the immunologic reasons for this difference. 
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CHAPTER 1: INTRODUCTION 
 
BKV is a member of the polyomavirus family. It was initially isolated in the urine of a 
renal transplant recipient with ureteral stenosis in 1971 and was named after the patient’s 
initials ‘B.K.’(1). Further studies showed infection with this virus may cause significant 
tissue changes in the renal allograft and subsequent graft loss(2). Infection with this virus 
begins with viral replication and shedding in the urine (viruria) which consequently 
progresses to blood stream infection (viremia) and eventually to polyomavirus associated 
nephropathy (PyVAN)(3). The frequency of viruria in renal transplant recipients is around 
30–40% while 10– 15% of recipients develop BK viremia, and only 2–5% develop 
PyVAN(4). The ranges in these figures may be related to variations in risk factors, screening 
strategies, and immunosuppressive regimens.  Regardless, BKV nephropathy is a known 
cause of allograft loss in kidney transplant recipients.  
Previous investigations evaluating risk factors for BKV infection and PyVAN have 
demonstrated inconsistent findings(5,6,7). Studies of recipient pairs who received kidney 
allografts from the same donor demonstrated that BKV infection can be a donor-derived 
infection (DDI)(8,9). In patients with donor origin BKV infection, early testing of urine 
samples from the recipients was helpful to identify those at risk for BKV-associated 
nephropathy(10). Recent data supported this hypothesis by demonstrating the transmission 
of the same genotype of BKV from the donors to the recipients (11).  BKV infection can also 
arise as a reactivated virus infection with recipient origin(12). Thus, the source of post-
transplant BKV infection could be either the donor or the recipient.  
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Previous studies identified risk factors of BKV infection including donor 
characteristics (female gender, African-American ethnicity, deceased donor vs living donor, 
ischemic-reperfusion injury, elevated BKV-specific antibody level as evidence of recent 
infection, Human Leukocyte Antigen (HLA) mismatches, recipient characteristics ( male 
gender, age older than 46 years, poor BKV-specific T-cell activity) and post-transplant 
variables (acute rejection and antirejection immunosuppressive therapy, ABO 
desensitization, cumulative doses of steroid, lymphocyte depleting antibodies, higher blood 
levels of immunosuppressive medications, tacrolimus vs cyclosporine, mycophenolate 
mofetil) (5 ,6,13, 14,15,16,13,17,18,19)  
In this cohort study, we determined the risk factors associated with BKV infection in 
renal transplant recipients. These risk factors include the variables related to the donor, 
recipient, allograft and post-transplant immunosuppression. We studied the association of the 
following variables with BKV infection in univariable and multivariable analysis: donor age, 
donor gender, recipient age, recipient gender, pre-transplant renal replacement therapy, HLA 
typing, HLA mismatch, cold ischemia time, cytomegalovirus serostatus at the time of 
transplantation, delayed graft function, donor status (living or deceased), rejection, ABO 
incompatibility, maintenance immunosuppression, and tacrolimus blood level. 
The remainder of this thesis is organized as follows:  Chapter 2 is a review of the peer-
reviewed literature on BK virus and PyVAN; Chapter 3 contains a manuscript intended for 
publication in a peer-reviewed journal, and Chapter 4 is a conclusion and general discussion 
of the work undertaken as part of this thesis.  The Research Ethics Board approval can be 
found in Appendix A.  Appendix B contains supplementary material for the manuscript in 
Chapter 3. 
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CHAPTER 2: LITERATURE REVIEW 
General Introduction to Polyomaviruses 
The human polyomaviruses, mainly JC virus (JCV) and BK virus (BKV), are ubiquitous 
in most human populations throughout the world. Polyomaviruses can cause invasive 
infection. In immunocompromised patients, JCV infection causes a demyelinating disease of 
the central nervous system (CNS) and progressive multifocal leukoencephalopathy 
(PML)(1)while BKV causes polyomavirus associated nephropathy (PyVAN) and ureteral 
stenosis in renal transplant recipients. BKV and JCV can both cause hemorrhagic cystitis in 
stem cell transplant patients(2). PML is an opportunistic infection in acquired 
immunodeficiency syndrome (AIDS) in HIV- positive patients.  New immunosuppressive 
treatments for non-transplant patients have also been shown to be associated with 
polyomavirus infection. Natalizumab is one of the new monoclonal antibodies that has been 
shown to be effective in the management of multiple sclerosis and Crohn’s disease. So far, 
more than 400 cases of natalizumab-related PML have been reported worldwide. (3). 
Recently, nine new human polyomaviruses have been isolated.  These new members of 
the genus were mainly named based on the site of discovery, their geographic origins, the 
diseases that they cause, or order of discovery: MWPyV (Malawi)(4), WUPyV (Washington 
University)(5), and KIPyV (Karolinska Institute)(6), STLPyV (St Louis), MCPyV (Merkel 
cell carcinoma)(7) , TSPyV (trichodysplasia spinulosa)(8); HPyV6, HPyV7, and HPyV9 
(human polyomaviruses 6, 7, and 9)(9,10). MCPyV is currently known as the cause of 
Merkel cell carcinoma, a cutaneous cancer that can involve both immunocompetent 
individuals and immunocompromised patients such as renal transplant recipients(7) .  
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BK Virus 
Previous studies showed as much as 85% of the general adult population are 
seropositive for BKV(11). The prevalence of BKV infection is initially low in children; 
however, the seroprevalence increases with age(11). Thus, elderly people are more likely to 
be seropositive than children, adolescents and adults. This discrepancy of seroprevalence and 
the frequency of BKV infection in different age groups are important in understanding the 
epidemiology of BKV infection.   
BKV does not usually cause a disease in immunocompetent individuals. However, 
infection with this virus is associated with several diseases in immunocompromised 
individuals including ureteral stenosis(12) and PyVAN(13) in renal transplant recipients and 
hemorrhagic cystitis(14) in stem cell transplant patients. 
BKV replicates in the urothelial cells and the rate of replication increases with 
immunosuppression. Approximately 15-35% of renal transplant recipients develop BK 
viruria(15). Detection of viruria before viremia is clear evidence of replication of the virus in 
the urinary tract system. However, the urinary viral load is not similar in all renal transplant 
patients, and only patients with a high level of viruria develop viremia.  One third of 
recipients with a high level of BK viruria (4 log10 genome equivalents (geq)/mL) develop 
BK viremia which is linked to polyomavirus associated nephropathy (PyVAN)(16). Since 
most current data is limited to immunocompromised patients, our understanding of the 
epidemiology of this virus is still incomplete. 
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Primary Infection and Transmission 
 
Primary infection with BKV occurs in childhood as evidenced by increasing BKV 
seroprevalence in the first decade of life(11). Natural BKV transmission is likely to occur via 
the respiratory or oral routes(17).  After primary infection, BKV can be detected in renal 
tubular epithelial cells, where they may remain latent.  
Respiratory and gastrointestinal (GI) transmission of BK virus has been confirmed in 
animal models.  However, GI transmission was delayed and not as effective as the 
respiratory model(18). BKV was also detected in oral fluids(17). BKV infection and 
replication of the virus was shown in salivary gland cells(17). These data suggested the 
potential oral route of transmission for BKV.  
In a study, stool samples and rectal swabs were collected from hospitalized pediatric 
patients. This study showed polyomaviruses are frequently detectable in stool samples. This 
finding demonstrates that fecal-oral transmission of BKV may also play a role(19). 
Some data suggest vertical transmission of BK from mother to newborn either during 
pregnancy or after delivery(20). The frequency of BK viruria increases to around 35% 
during pregnancy suggesting the risk of vertical transmission(21). Animal data also showed 
vertical transmission of polyomaviruses(22,23). BK virus can cross the placenta and become 
latent in fetal organs(24). Recent data showed probable vertical transmission of BKV in 
human(25). On the other hand, population-based studies showed the same genotypes of BKV 
in urine samples collected from Japanese-Americans and from other southern Californians in 
Los Angeles. Since this genotype (subtype I subgroup Ib-2) is rare in native Japanese, this 
data suggest transmission outside of the family is common(26).  
10 
 
 
Immunology 
 
The immune system plays an essential role in the control of BKV replication and 
resolution of PyVAN. CD4+ and CD8+ T cells both are main components of cell mediated 
immunity to control BKV. T-cell response targets both nonstructural and viral capsid 
proteins and this response can be measured via ELISPOT and tetramer 
staining(27).Cytotoxic T-cells sensitized to BK virus antigens were detected in healthy 
volunteers and renal transplants(28).   In kidney transplant recipients, a considerable CD8 
response was associated with lower BK viral loads in blood and urine, while poor response 
was associated with high BK titers and viral persistence(29).  Thus, reduction of 
immunosuppression appears to be associated with decreases in viruria and viremia.  
Cell mediated immunity plays a pivotal role in controlling BKV infection. Cytotoxic T 
cells (CTL) kill the cells infected with BKV after recognition of damaged segments of viral 
DNA(30). This finding helped researchers develop cellular immunotherapy for the 
management of BKV infection and PyVAN. Ex vivo reactivation of BKV-specific CTL was 
developed from BKV-seropositive healthy donors and renal transplant recipients through 
stimulation with dendritic cells (antigen presenting cells) pulsed with inactivated BKV. 
Those cytotoxic T cell lines demonstrated BKV specificity, as an efficient lysis of BKV-
infected targets(31) . 
Infected dendritic cells may induce CTLs(32). Interestingly, the BKV CTL epitopes 
bear remarkable homology with the CTL epitopes of JCV(29). The same population of T-
cells are probably effective against these two closely related viruses. However, it is not clear 
why suppression of CMI after transplantation causes replication of BKV but not JCV. (27).  
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Different immunosuppressive regimens have been shown to be associated with 
BKV infection and PyVAN. Receiving OKT3, rATG and alemtuzumab, tacrolimus and 
MMF significantly increase the risk of BKV infection(33, 34). It appears that the role of 
these immunosuppressive medications is mainly through decreasing the function of CMI. 
The role of antibody mediated immunity was also demonstrated in polyomavirus 
infection. Treatment with immunoglobulins can control the BKV infection and 
PyVAN(35,36,37). On the other hand, treatment of acute rejection with high doses of 
immunoglobulin was associated with increased BK viral load and worsening of PyVAN(38). 
Patients with PyVAN showed the highest frequencies of BKV-specific T cells at time of 
recovery, the highest rise in BKV-specific IgG and persistence of enhanced  IgM levels(39). 
These studies provided excellent evidence to support the roles of CMI and AMI to control 
BKV infection. 
Allograft Rejection 
Acute rejection is an independent risk factor for BK virus infection after 
transplantation(33,40).  Cell–mediated, antibody-mediated or steroid resistant rejections all 
increase the risk of BKV infection and PyVAN(33). The effect of allograft rejection may be 
related to the treatment of rejection with immunosuppressive medication and not necessarily 
rejection itself(41). 
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Blood Groups and ABO-incompatibility 
 
When blood groups of donor and recipient are not matched (ABOi or ABO 
incompatibility), the recipient is at a risk of allograft rejection. Generally, recipients with 
blood group O and B are at a higher risk of rejection. Patients with ABOi should receive 
medical treatment and immunosuppression before and after transplantation. This treatment is 
called desensitization which includes removing antibodies from blood circulation 
(plasmapheresis), spleen removal (splenectomy), intravenous immunoglobulin, and 
immunosuppression. 
It has been demonstrated that ABO-incompatible kidney recipients are at greater risk for 
BKVAN than HLA-incompatible kidney recipients (42). However, it is not clear that ABOi 
itself increases the risk or whether a higher incidence of BKV infection and PyVAN in ABOi 
patients is related to desensitization. ABOi renal transplants are more likely to develop CMV 
infection, BKV-associated nephropathy, and even severe sepsis. T-cell depletion due to 
desensitization may increase the risk of T-cell-dependent infectious diseases. Elimination of 
B cells serving as antigen-presenting cells, thus causing impaired T-cell activation, will 
affect alloreactive T-cell activation and increases the chance of infection(43). 
A study which included 26 ABOi renal transplant recipients and continued follow-up for 
one year after transplantation demonstrated a higher risk of BKV infection in patients 
receiving desensitization(44).  In that study, patients received an intensified desensitization 
with rATG which was associated with significant immunosuppression. To resolve this risk, a 
study suggested using everolimus rather than mycophenolic acid in immunosuppression to 
decrease the risk of BKV infection(45).  
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A study from John Hopkins Hospital compared the incidence of BKV infection 
between 62 ABOi and 221 HLA incompatible patients. That study showed the risk for BKV 
infection is greater among ABOi than HLA-incompatible patients (17.7% vs. 5.9%)(42). 
This is the only study that demonstrated a significant association between ABOi and BKV 
infection and compared by HLA incompatibility. 
HLA Antigens and BKV Infection 
 
HLA or Major Histocompatibility Complex (MHC) are groups of genes in animals and 
humans that encode a variety of cell surface markers, antigen-presenting molecules, and 
other proteins involved in immune function. The HLA system is divided into 3 regions: class 
I, class II, and class III. The class I region contains the genes encoding the “classical” class I 
HLA antigens: HLA-A, B, and C. 
Except for red blood cells and platelets, all human body cells have HLA class I. The 
class II region contains the genes that encode the HLA class II molecules including HLA-
DP, DQ, and DR. Class II antigens are expressed on B cells, dendritic cells, and monocytes 
but can be induced during inflammation on many other cell types that normally have no 
expression. 
The following facts explain the complexity of the HLA system in our body: 
1. HLA class I contains an alpha chain and a beta chain. The alpha chain is coded for 
by genes within the MHC in chromosome 6; however, the beta chain, beta-2 microglobulin, 
is encoded on chromosome 15 and not in the MHC. 
2. Each class contains several gene loci. Some HLA loci are very polymorphic; for 
example, over 4300 alleles are known for HLA-B and over 1900 alleles for HLA-DRB1. 
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3. We have polymorphic alpha and beta chains in DQ and DP antigens, which 
can make various combinations. 
4. By contrast, DR dimers have an essentially invariant alpha chain, but extreme 
polymorphic beta chain. 
5. The number of DR genes varies among people.  
All these factors demonstrate the likelihood of interaction between HLA variables. The 
role of HLA in BKV infection has been evaluated in several investigations. Renal transplant 
patients may excrete some HLAs in their urine. Excretion of some HLAs in urine was shown 
before detection of allograft damage. Increased excretion of cells with HLA-DR surface 
antigens was associated with intragraft tubulointerstitial inflammation in patients with 
PyVAN(46). This suggests the role(s) of HLA molecules in inflammatory changes of the 
allograft after BKV infection.  
Donor-recipient mismatching of HLA-B and HLA-DR may increase the risk of BKV 
infection (33). On the other hand, donor-recipient matching of HLA-A2, HLA-B44 and 
HLA-DR15 were shown to be associated with a lower risk of BKV infection(47). It has been 
recently shown recipient age younger than 18 years, male sex, HLA A, B, DR mismatches of 
4 or greater, acute rejection, and the use of depleting antibody induction were main risk 
factors for BKV infection(48). This study showed the risk of BKV infection increases with 
rising of HLA mismatches. The number of HLA mismatches seems to be the strongest 
independent predictors of BK viremia(49,40). Recent data interestingly showed that the 
absence of HLA C7 increases the risk of sustained viremia(49). HLA C7 seems to provide a 
protective role against BKV infection. On the other hand, patients with ESRD secondary to 
diabetes and patients treated with sirolimus had lower odds of BKV infection(48).  
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BK Viruria and Viremia 
Up to 20% of asymptomatic immunocompetent individuals may develop BK 
viruria(50), but viral shedding in the urine is higher in renal allograft recipients (57%) which 
correlates with the degrees of immunosuppression(51). In the urine of patients who are HIV 
positive, BK viral load increases with decreasing CD4+ T-cell counts(52). Although BKV is 
usually not detected in the peripheral blood of immunocompetent patients, the detection of 
BKV DNA in the plasma of renal transplant patients is an indication of development of 
PyVAN(53). The risk for viremia is higher in patients with viruria (particularly for viral load 
(VL) >4 log/mL) treated with tacrolimus(51). BK viremia regardless of allograft function is 
considered as presumptive BK nephropathy(53). A BK viral load more than 4 log copies/mL 
has been shown to be strongly associated with biopsy-proven PyVAN (16). 
Immunosuppression 
Previous studies assumed association of different immunosuppressive regimens with 
BKV infection. Consequently, the researchers used heterogeneous methods of 
immunosuppression reduction associated with a wide range of dose change (54,55). Most 
previous studies which showed effectiveness of immunosuppression reduction did not have 
control groups(56,54,57,55) or their sample sizes were small(57,58).  Immunosuppression 
appears to be the most important risk factor for BKV infection (12).  In a RCT, 200 adult 
renal transplants were followed for one year after transplantation. Of these, 23 patients 
(11.5%) developed BK viremia. The protocol of immunosuppression reduction included 
discontinuation of AZA or MMF. In case of failure to clear viremia in 4 weeks, the doses of 
CNIs were tapered. Using this approach, 95% of patients were able to clear viremia but 10 
cases of rejection occurred (59).   
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To demonstrate which immunosuppressive medications are more associated with 
BKV infection, researchers began immunosuppression reduction with CNIs rather than 
MMF or AZA. In a cohort of 38 patients, decreasing immunosuppression was evaluated in 
three stages a) decreasing the dose of tacrolimus to achieve the trough level of 6-8ng/ml then 
b) further dose reduction of tacrolimus (targeting trough level of 4-6 ng/ml and eventually c) 
decreasing the dose of MMF by 50%. This approach was associated with 92% of clearance 
of viremia and 8.6% frequency of rejection(56). This study had no control group. This study 
supported the association between tacrolimus blood level and BKV infection. 
In an uncontrolled cohort of 62 patients, progressive decreasing dose of tacrolimus 
targeting the level of 5–8 ng/mL as well as decreasing the dose of MMF targeting 600 
mg/m2/day was associated with 100% clearance of viremia (16). This study showed 
probable effects of tacrolimus blood level and MMF in the pathogenesis of BKV infection 
and PyVAN. 
Some centers preferred cessation of immunosuppressive medications rather than dose 
reduction. In a retrospective analysis, withdrawal of an immunosuppressive medication 
(mostly CNIs) in 17 patients was compared by reduction of immunosuppression (mostly 
MMF) in 18 patients. Withdrawal of immunosuppressive medications was significantly 
associated with better graft survival (one-year graft survival of 87.8% versus 56.2%, P = 
0.03). Heterogeneous intervention, retrospective analysis and low number of patients were 
main limitations of this study(54). Unfortunately, this study did not show which components 
of immunosuppression are more likely associated with BKV infection and PyVAN. 
Enhancement of graft function was likely secondary to improvement of BK viremia. 
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Unfortunately, immunosuppression reduction may not be necessarily associated 
with good outcomes. In a cohort of 11 patients with BK viremia, this approach was 
associated with rejection in 3 patients and one graft loss(57). This study showed decreasing 
immunosuppression may not be a safe approach and may increase the chance of graft loss.  
A recent study from China showed excellent effect of immunosuppression reduction. In 
this study, patients with presumptive PyVAN (BKV infection) were treated with 30-50% 
reduction in doses of tacrolimus and/or mycophenolate mofetil and were monitored for BKV 
every 3-6 months. All patients were followed for 5 years. Overall, 5-year patient and graft 
survival rates were 95.6% and 92.1%, respectively(55).  The protocol for 
immunosuppression was quite heterogeneous with a wide range of immunosuppression 
reduction. This study did not have a control group. Their findings not only showed the effect 
of the doses of immunosuppressive medications in BKV infection and PyVAN. 
Interestingly, with reducing the magnitude of the risk factor (doses of immunosuppressive 
medications) the outcome (PyVAN) was reversible and this effect remained.  
Some studies compared reduction of immunosuppression with medical treatment of 
BKV infection and PyVAN. In one study, 14 renal transplants with significant BK viremia 
received ciprofloxacin plus intravenous immunoglobulin. The control group (19 recipients) 
was treated with immunosuppression reduction. One-year graft survival and the rate of 
rejection were similar(58).  This study did not have enough power to show the risk of 
rejection due to a small number of patients in each group. The findings of this study showed  
reducing of immunosuppression may reverse PyVAN although other interventions such as 
intravenous immunoglobulin and fluoroquinolones affected the results. 
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Early detection of sustained BKV-viremia is probably the key factor for the 
achievement of immunosuppression reduction approaches. Undeniably, all studies that 
reported favorable outcomes of immunosuppression reduction detected BKV-viremia early 
post-transplant, allowing for appropriate therapeutic intervention(60,57,59). However, if the 
diagnosis of BKV infection and PyVAN are made at a later stage, reduction of 
immunosuppression is likely to be less successful, probably due to more progressive 
irreversible injury of the renal allograft(54). Overall, these findings support the association 
between immunosuppression and BKV infection but also demonstrate reversibility of the 
outcome when we decrease the dose of the risk factor. 
 
Medications with Anti-BKV Effects 
 
Cidofovir is an antiviral medication that may be used for treatment of other viral 
infections such as CMV(61).  This medication is an acyclic nucleoside phosphonate that acts 
as an inhibitor of DNA synthesis. It inhibits replication of BKV(62). Brincidofovir (BCV) is 
an oral form of this medication. BCV is ether-lipid ester conjugated prodrug of cidofovir. 
The lipid moiety of BCV is important for its pharmacokinetic properties, facilitating rapid 
uptake by cells and allowing oral administration(63). Recently, some clinical trials were 
carried out to show the efficacy of this medication against CMV infection. Expectedly, 
patients who were included in those studies did not develop BKV infection(64). The effect 
of BCV on CMV is related to inhibition of DNA polymerase but BKV utilizes host cell 
DNA polymerase and the anti-BKV mechanism of BCV is not clear. It is important to 
consider the effects of these medications in the risk analysis for BKV infection and PyVAN.  
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Leflunomide is an anti-metabolite, antirheumatic disease modifying 
agent. Leflunomide inhibits pyrimidine synthesis resulting in anti-proliferative and anti-
inflammatory effects. Its metabolite, teriflunomide (A77 1726) has been found to reduce or 
stop the replication of BK in vitro and in animal models(65). Although the data related to 
efficacy of this medication showed quite variable findings, patients who are on this 
medication theoretically may be at a low risk of BKV infection.  
Sirolimus and everolimus are two medications belonging to the family of mTOR 
inhibitors. Although they are immunosuppressive medications , they inhibit BKV replication 
in urothelial cells(66, 67).  
As mentioned above, intravenous immune globulin (IVIG) may control BKV 
infection(35,68, 69). This medication is a pooled product which contains antibodies against 
different pathogens. It also contains antibodies against HLA antigens which inhibit rejection. 
This medication also has some immunomodulatory effects. 
In conclusion, the human polyomaviruses have been shown to be common in human 
populations since their discovery in the 1950s.   Many donor and recipient characteristics 
have been shown to have protective or risk effects in the context of BK virus infection and 
kidney transplantation.  The next chapter of this thesis is a report of an original cohort study 
undertaken to add to our understanding of these risk and protective factors.    
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Introduction 
BK virus is a polyomavirus which was initially isolated in the urine of a renal transplant 
recipient with ureteral stenosis (1,2). It was subsequently shown that BKV infection begins 
with replication in urothelial cells (3). Viral replication and shedding in the urine (viruria) 
consequently progresses to blood stream infection (viremia) and eventually to polyomavirus 
associated nephropathy (PyVAN) (4). The frequency of viruria in renal transplant recipients 
is estimated to be 30–40% while 10– 15% of recipients develop BK viremia, and 2–5% 
develop PyVAN(5). The difference in the reported incidence rates seems to be related to risk 
factors, magnitude of exposure and screening strategies(6). BKV nephropathy is a 
considerable cause of allograft loss in kidney transplant recipients(7).  
Previous investigations evaluating risk factors for BKV infection and PyVAN have 
demonstrated inconsistent findings(8,9,10). Some studies demonstrated that BKV infection 
can be a donor-derived infection (DDI) (11,12). Recent data demonstrated the same 
genotype of BKV in donors and recipients(13). Early post-transplant urine PCR (polymerase 
chain reaction) can detect BK viruria in recipients with donor-derived BKV infection  (14). 
On the other hand,  BKV infection can also represent a reactivated infection with recipient 
origin(15). 
Previous studies showed probable risk factors of BKV infection including donor 
characteristics (female gender, deceased donor, ischemia-reperfusion injury, elevated BKV-
specific antibody level, HLA-mismatches), recipient characteristics (male gender, age, poor 
BKV-specific T-cell activity) and post-transplant variables (rejection, immunosuppression, 
ABO desensitization, cumulative doses of steroid, lymphocyte depleting antibodies, 
tacrolimus, mycophenolate mofetil) (8 ,9,16, 17,18,19,16,20,21,22).  
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In this cohort study, we evaluated the roles of different variables that may 
increase or decrease the risk of BKV infection and PyVAN in renal transplant recipients 
using univariable, multivariable and time-dependent analyses. In addition to examining 
many previously identified variables, we also analyzed for potential differences in risk 
associated with pre-transplantation dialysis modality, HD versus PD. 
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Materials and Methods 
This study was reviewed by the institution’s Research Ethics Board (REB) and data 
collection started after approval. We included all adult patients who received renal 
transplantation at London Health Sciences Centre between July 1 2012 and July 1 2014. We 
continued follow-up for one year following transplantation. Our main objective in this cohort 
study was to determine the risk factors of BKV infection in the first year after renal 
transplantation.  
We estimated the association between the following variables and BKV infection: donor 
age, donor gender, donor vital status (living vs. deceased), recipient age, recipient gender, 
pre-transplant dialysis modality, HLA typing, HLA mismatch, cold ischemia time, 
cytomegalovirus serostatus at the time of transplantation, delayed graft function, rejection, 
ABO incompatibility, maintenance immunosuppression, and tacrolimus blood level. 
Demographic information of recipients and donors was collected at the time of initial 
assessment.  Our post-transplantation follow-up included physical examination, laboratory 
tests, evaluation of allograft function, updating the medication list, and finally 
documentation of all clinical findings, recommendations and treatment plans. Relevant 
medical history including underlying diseases, post-transplant events and biopsy-proven 
rejection episodes were also recorded. All information was documented in clinical 
assessment forms. Subsequently, we transferred all data to an electronic medical record 
system. New abnormal findings were explained to the patient and followed by a physician at 
the next scheduled clinical visit.  
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Blood samples were obtained at regular intervals. Laboratory follow-up included 
a complete blood count (hemoglobin, hematocrit, red blood cell count, white blood cell 
count, white blood cell differential, and platelet count), electrolytes, urea, creatinine, serum 
BK-PCR and whole blood tacrolimus trough concentration. Subsequently, we determined 
average tacrolimus level for each patient. Based on the central limit theorem, we calculated 
mean ±SD of average tacrolimus levels for patients who developed or did not develop BKV 
infection. We performed this analysis in the first three months and then 4-12 months after 
transplantation. 
Our routine screening protocol at LHSC includes BKV-PCR on plasma every 1-3 
months in the first 2 years after transplantation and subsequently every year until the end of 
the 5th post-transplant year. Our protocol also includes BKV-PCR in patients with allograft 
dysfunction or patients who require allograft biopsy. Histopathologic assessment for BKV is 
routinely included in all renal allograft biopsies. In case of detectable viremia, we regularly 
monitored BKV viral load and allograft function.  
Diagnosis of BKV infection 
 
DNA extraction, using 400 µl of plasma, was performed on the MagNA Pure Compact 
instrument (Roche Diagnostics, Indianapolis, IN) with the MagNA Pure Total Nucleic Acid 
Isolation Kit I (Roche); samples were eluted in 50 µl.  The RealStar® BKV PCR (Altona 
Diagnostics, Kit 1.2) assay was performed on a Lightcycler 2.0 instrument (Roche) with BK 
viral load reported in copies/ml based on the provided standards. The RealStar®BKV PCR 
Kit 1.2 is an in vitro diagnostic assay, based on real-time PCR, for the diagnosis of BKV 
infection and quantification of BKV DNA(23).  
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Statistical analysis 
The dependent variable was BKV infection observed over the 12 months of follow-up.  
In univariable analyses, Chi-square and Fisher’s exact tests were used to estimate the 
association between categorical variables, and t-tests and Mann-Whitney tests were used 
with continuous variables.   Relative risk was calculated as ratio of the probability of BKV 
infection occurring in patients who were exposed to a probable risk factor to the probability 
of BKV infection occurring in a comparison, non-exposed group. We performed time-
dependent analyses including Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) and 
Tarone-Ware tests. In this analysis, the variable of time was the interval between 
transplantation and BKV infection. In Cox proportional hazard models, we estimated the 
hazard ratios of BKV infection for risk factors. In our final multivariable model, we included 
variables that were associated with BKV infection in univariable analysis with significance 
level of p<0.1. In all hypothesis tests, p-values <0.05 were considered statistically 
significant. 
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Results 
This cohort comprised 175 renal transplant patients, of whom 40 (22.9%) developed 
BKV viremia in the first year after transplantation. Of these, 5 patients developed biopsy-
proven PyVAN. One out of 8 patients who received renal/pancreas transplantation developed 
BKV infection (12.5%). Median interval (Inter Quartile Range25%-75%) between 
transplantation and BKV infection was 100 (61-170) days. No patient received antiviral 
medications with activity against BKV such as cidofovir or brincidofovir.  
No patient developed allograft failure (requiring retransplantation or returning to renal 
replacement therapy including hemodialysis or peritoneal dialysis). One patient passed away 
due to complicated sepsis after clostridium difficile infection. This patient developed BKV 
infection before clostridium difficile infection. 
Demographic variables 
 
Table 1 provides the characteristics of recipients with BKV infection and unaffected 
patients.  Crude (unadjusted) estimates of association (relative risks) are also provided in 
table 1. P-values are based on Chi-square tests. 
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Table 1- Characteristics of recipients with BKV infection and unaffected patients 
and crude (unadjusted) estimates of association (relative risks). 
Variable, n (%) No BKV infection, n=135  BKV infection, n=40    Relative risk   p-value, CI95% 
Donor gender 
Male 
Female 
 
86 (76.1) 
47 (78.3) 
 
27(23.9) 
13 (21.7) 
1.1 0.5-1.6 
Recipient gender 
Male 
Female 
 
79 (71.2) 
56 (87.5) 
 
32 (28.8) 
8 (12.5) 
2.3 1.13-4.7 
Donor         
                  DCD  
NDD 
                  Living donor 
                    
Living donor vs. 
Non-living donor 
 
47 (77) 
57 (73.1) 
31 (86.1) 
 
31(86.1) 
105 (74.8) 
 
14 (23) 
21(26.9) 
5 (13.9) 
 
5(13.9) 
35 (25.2) 
 
 
 
 
 
0.5  
0.3 
 
 
 
 
0.2-1.3 
CMV serostatus* 
D+/R+ 
D+/R- 
D-/R- 
D-/R+ 
CMV D+/R-  
vs Other  
 
29 (76.3) 
29 (69) 
42(79.2) 
35 (87.5) 
  
29 (69) 
106 (79.7) 
 
9 (23.7) 
13 (31) 
11 (20.8) 
5 (12.5) 
 
13(31) 
27 (20.3) 
 
 
 
 
 
 
1.5 
0.2 
 
 
 
 
 
0.9-2.6 
DGF 23 (79.3) 6 (20.7) 0.9 0.4-1.9 
Blood groups, recipients 
A  
B 
AB 
O 
 
O vs.  
non-O 
 
B vs.  
non-B 
 
52 (76.5) 
18 (64.3) 
6 (100) 
59 (80.8) 
 
59(80.8) 
76 (74.5) 
 
18 (64.3) 
117 (79.6) 
 
16 (23.5) 
10 (35.7) 
0 
14 (19.2) 
14 (19.2) 
26 (25.5) 
 
 
10 (35.7) 
30(20.4) 
 
 
 
 
 
 
0.7 
 
 
1.7 
0.2 
 
 
 
 
 
0.4-1.4 
 
 
0.96-3.1 
Blood groups, donors 
A 
B 
AB 
O 
B vs. 
Non-B 
 
49 (76.6) 
13(56.5) 
3(100) 
68(81.9) 
13(56.5) 
120 (80) 
 
15(23.4) 
10(43.5) 
0 
15(18.1) 
10(43.5) 
30 (20) 
 
 
 
 
 
2.2 
0.06 
 
 
 
 
1.2-3.8 
 
ABO  
Compatible 
Incompatible 
 
131 (76.6) 
2 (100) 
 
40 (23.4) 
0 
 
0.7 
 
0.05-9.0 
Dialysis 
Hemodialysis (HD) 
Peritoneal dialysis (PD) 
Preemptive (PE) 
 
HD vs. 
Non-HD© 
 
81 (71.7) 
40 (87) 
14 (87.5) 
 
81(71.7) 
54(87.1) 
 
32 (28.3) 
6 (13) 
2 (12.5) 
 
32(28.3) 
8(12.9) 
 
 
 
 
 
2.2 
0.06 
 
 
 
 
1.1-4.5 
Retransplantation 
Yes 
No 
 
24 (85.7) 
111 (75.5) 
 
4 (14.3) 
36 (24.5) 
0.6 0.2-1.5 
Allograft rejection 36 (26.7) 5 (12.2%) 0.5 0.2-1.1 
*Serostatus for 2 patients were indeterminate; © Comparison HD vs. non-HD including PD and PE, 
p=0.02 
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Regarding quantitative variables, table 2 provides the difference between 
recipients with BKV infection and unaffected patients. These variables include recipient age, 
donor age, cold ischemia time, interval between transplantation and ureteral stent removal, 
tacrolimus trough levels in the first 3 months and 4-12 months after transplantation.  Mann-
Whitney tests were used to compare patients who did and did not develop BKV infection. 
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Table 2- Comparison of quantitative variables between recipients with BKV 
infection and unaffected patients 
Variable No BKV infection,   
n=135 
BKV infection, 
n=40 
p-value 
Median age, years (range) 
   Recipients 
       Overall 
       From deceased donors 
       From living donors 
Median age, years (range) 
   Donors 
     Overall 
     Deceased 
     Living 
 
 
56 (16-82) 
56 (16-82) 
48 (26-71) 
 
 
49 (1-72) 
49 (1-69) 
49 (26-71) 
 
 
 
 
52 (14-79) 
54 (14-79) 
56 (29-67) 
 
 
51 (12-74) 
49 (12-74) 
60 (58-64) 
 
 
 
  0.07 
  0.3 
  0.2 
 
  
  0.4 
  0.9 
0.0001 
     Median cold ischemia time (minutes) 480(14-1440)   605(168-1290)   0.4 
      Median interval between transplantation and ureteral stent 
removal, (range) 
35 (12-68) 
 
37 (22-82)   0.7 
      Median trough tacrolimus level (range) in the first 3 months 
after transplantation, ng/ml 
6.05 (3.9-10.9)   6.1 (4.3-8.8)   0.4 
  Median trough tacrolimus level (range) 4-12 months after 
transplantation, ng/ml 
5.6(3.1-9.0) 5.6(3.6-9.5)   0.4 
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Recipient HLA  
 
Table 3 demonstrates the association between HLA mismatches and BKV infection. In 
this table patients with one or two mismatches were compared with no mismatch. Table 4 
shows the frequencies of specific HLAs in recipients who developed BKV infection or 
remained BKV free.  
HLA- Cw4 (RR: 2.3, CI 95%: 1.4-3.8) and HLA-B35 (RR: 2.5, CI95%: 1.4-4.2) were 
significantly associated with BKV infection. However, HLA- Cw6 (RR:1.6, CI 95%: 0.9-2.8) 
and HLA-Cw7 (RR: 1.09, CI95%: 0.6-1.8) did not increase the risk. P-values are based on 
Chi-square tests. 
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Table 3- Impact of HLA mismatching on the incidence of BKV infection.  
VARIABLE NO BKV INFECTION, 
N=135 
BKV INFECTION, 
N=40 
P-VALUE 
  HLA-A mismatch 
0 
1 
2 
 
19 (82.6) 
53 (75.7) 
60 (75.9) 
 
4 (17.4) 
17(24.3) 
19 (24.1) 
0.7 
  HLA-B mismatch 
0 
1 
2 
 
10 (83.3) 
38 (73.1) 
83 (77.6) 
 
2 (18.7) 
14 (26.9) 
24 (22.4) 
0.6 
  HLA-C mismatch * 
0 
1 
2 
 
≤1 
2 
 
20 (80) 
43 (66.2) 
69 (84.1) 
 
63(70) 
69(84.1) 
 
5 (20) 
22 (33.8) 
13 (15.9) 
 
27(30) 
13(15.9) 
0.03 
 
 
 
 
0.03 
  Total class I mismatch 
0 
1 
2 
3 
4 
5 
6 
 
<3 
≥ 3 
 
5(71.4) 
2(100) 
12 (92.3) 
14.9 (60.9) 
33 (76.7) 
38 (76) 
28 (82.4) 
 
19 (86.4) 
113 (75.3) 
 
2 (28.6) 
0 
1 (7.7) 
9 (39.1) 
10 (23.3) 
12 (24) 
6 (17.6) 
 
3 (13.6) 
37 (24.7) 
0.3 
 
 
 
 
 
 
 
 
0.2 
 
  HLA-DR mismatch 
0 
1 
2 
 
20 (80) 
42 (73.7) 
70 (77.8) 
 
5 (20) 
15 (26.3) 
20 (22.2) 
0.7 
  HLA-DQ mismatch 
0 
1 
2 
 
26 (78.8) 
53 (70.7) 
53 (82.8) 
 
7 (21.2) 
22 (29.3) 
11 (17.2) 
0.2 
* Recoding of the variable to ≥ 1 mismatch did not show a significant difference between patients who 
developed and did not develop BKV infection (RR=0.8, CI 95%:0.4-1.9). 
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Table 4- The association between HLAs in recipients and BKV infection 
VARIABLE, 
N (%) 
NO BKV INFECTION, 
N=131 
BKV INFECTION, 
N=41 
RELATIVE 
RISK 
  CI95% 
HLA-A1 
Absent  
Present 
 
97 (81.5) 
38 (67.9) 
 
22 (18.5) 
18 (32.1) 
1.7   1.1-2.9 
HLA-A2 
Absent  
Present 
 
74 (77.1) 
61 (77.2) 
 
22 (22.9) 
18 (22.8) 
0.9   0.6 -1.8 
HLA-A3 
Absent  
Present 
 
107 (77) 
28 (77.8) 
 
32 (23) 
8 (22.2) 
0.9   0.5-1.9 
HLA-B8 
Absent  
Present 
 
106 (77.9) 
26 (72.2) 
 
30 (22.1) 
10 (27.8) 
1.2   0.7-2.3 
HLA-B35 
Absent  
Present 
 
120 (80.5) 
12 (52.2) 
 
29 (19.5) 
11 (47.8) 
2.5   1.4-4.2 
HLA-Cw4 
Absent  
Present 
 
113 (81.3) 
19 (57.6) 
 
26 (18.7) 
14 (42.4) 
2.3   1.4-3.8 
HLA-Cw6 
Absent  
Present 
 
110 (79.1) 
22 (66.7) 
 
29 (20.9) 
11 (33.3) 
1.6 
 
  0.9-2.8 
HLA-Cw4 or 
Cw6 
Absent  
Present 
 
95 (85.6) 
37 (60.7) 
 
16 (14.4) 
24 (39.3) 
2.7   1.6-4.7 
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Table 5- Correlations between variables  
 
Recipient 
age 
HLAC4 HLAB35 HD vs 
NON-HD 
Gender Donor BG 
B vs non-B 
HD_HLA C4  HLA B35_C4  HLAA1 HLA C two 
MM or 
NOT 
Recipient age 
Correlation 1 .017 -.028 .034 .012 -.052 .029 .003 .008 .170* 
Sig. (2-tailed) 
 
.823 .711 .654 .873 .500 .706 .971 .918 .026 
N 175 172 172 175 175 173 172 172 175 172 
HLAC4 
Correlation .017 1 .749** -.124 .099 .103 .934** .772** -.127 .023 
Sig. (2-tailed) .823 
 
.000 .106 .196 .181 .000 .000 .097 .763 
N 172 172 172 172 172 170 172 172 172 172 
HLAB35 
Correlation -.028 .749** 1 -.077 .117 .045 .726** .975** -.091 .104 
Sig. (2-tailed) .711 .000 
 
.315 .126 .563 .000 .000 .237 .175 
N 172 172 172 172 172 170 172 172 172 172 
HD vs NON-
HD 
 Correlation .034 -.124 -.077 1 -.008 -.035 .025 -.066 .055 -.075 
Sig. (2-tailed) .654 .106 .315 
 
.915 .648 .740 .393 .467 .328 
N 175 172 172 175 175 173 172 172 175 172 
Gender 
Correlation .012 .099 .117 -.008 1 .088 .095 .106 .063 .086 
Sig. (2-tailed) .873 .196 .126 .915 
 
.247 .214 .165 .407 .261 
N 175 172 172 175 175 173 172 172 175 172 
Donor BG B 
vs non-B 
Correlation -.052 .103 .045 -.035 .088 1 .043 .052 -.016 .031 
Sig. (2-tailed) .500 .181 .563 .648 .247 
 
.579 .497 .833 .686 
N 173 170 170 173 173 173 170 170 173 170 
HD-C4 
Correlation .029 .934** .726** .025 .095 .043 1 .748** -.110 -.001 
Sig. (2-tailed) .706 .000 .000 .740 .214 .579 
 
.000 .151 .995 
N 172 172 172 172 172 170 172 172 172 172 
HLA B35_C4 
Correlation .003 .772** .975** -.066 .106 .052 .748** 1 -.080 .088 
Sig. (2-tailed) .971 .000 .000 .393 .165 .497 .000 
 
.295 .254 
N 172 172 172 172 172 170 172 172 172 172 
HLAA1 
Correlation .008 -.127 -.091 .055 .063 -.016 -.110 -.080 1 -.042 
Sig. (2-tailed) .918 .097 .237 .467 .407 .833 .151 .295 
 
.583 
N 175 172 172 175 175 173 172 172 175 172 
HLA C two 
MM or NOT 
Correlation .170* .023 .104 -.075 .086 .031 -.001 .088 -.042 1 
Sig. (2-tailed) .026 .763 .175 .328 .261 .686 .995 .254 .583 
 
N 172 172 172 172 172 170 172 172 172 172 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Survival analysis 
 
We analyzed the effect of hemodialysis (HD) on the time- to-event of BKV infection. 
We also compared this effect with the effects of preemptive transplantation (PE) and 
peritoneal dialysis (PD).  Figure 1 demonstrates the survival functions of HD, PD and PE on 
the time-to-event of interest (BKV infection).  
We repeated the analysis comparing the patients who received HD and PD before 
transplantation. Figure 2 demonstrates the survival functions of HD vs. PD on the time-to-
event of interest (BKV infection). Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon) 
and Tarone-Ware tests all showed a significant difference between HD and PD patients. 
There was no significant difference between PE and HD patients with a higher risk 
associated with pre-transplantation HD. Figure 3 demonstrates this finding in detail.  
We performed similar analysis to compare the effect of living donors (LD) vs. non-LD 
(DCD and NDD). Figure 4 shows receiving organ from LD vs. non-LD did not significantly 
change the risk of BKV infection in time-dependent analysis.  
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 Chi-
Square 
Degree of 
freedom 
p-value 
Log Rank (Mantel-Cox) 5.32 2 .07 
Breslow (Generalized 
Wilcoxon) 
5.38 2 .07 
Tarone-Ware 5.36 2 .07 
 
Figure 1: Survival functions in those receiving preemptive transplantation (PE) and two 
methods of renal replacement therapies before transplantation including hemodialysis (HD) 
and peritoneal dialysis (PD) on post-transplant BKV infection.  
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Test Chi-
Square 
Degree of 
freedom 
p-value 
Log Rank (Mantel-Cox) 3.93 1 .05 
Breslow (Generalized 
Wilcoxon) 
3.79 1 .05 
Tarone-Ware 3.87 1 .05 
 
 
Figure 2: Survival functions in those receiving pretransplant peritoneal dialysis (PD) vs. 
hemodialysis (HD) on post-transplant BKV infection 
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Figure 3: Survival functions in those receiving preemptive transplantation (PE) vs. 
pretransplant hemodialysis (HD) on post-transplant BKV infection 
 
  
Test Chi-
Square 
Degree of 
freedom 
p
-value 
Log Rank (Mantel-Cox) 
1.84 1 .
17 
Breslow (Generalized 
Wilcoxon) 
2.06 1 .
15 
Tarone-Ware 
1.96 1 .
16 
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Test Chi-
Square 
Degree of 
freedom 
p-value 
Log Rank (Mantel-
Cox) 
1.88 1 .17 
Breslow (Generalized 
Wilcoxon) 
1.77 1 .18 
Tarone-Ware 1.83 1 .18 
 
Figure 4: Survival functions in recipients of living donor (LD) vs. Donation after cardiac 
death (DCD) and Donation after neurological determination of death (NDD) 
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Multivariable analysis 
 
We performed Cox proportional hazard test in multivariable analysis. In univariable 
analyses, we found significant roles of HLA- B35, HLA-Cw4, HLA-C mismatch, chronic 
pretransplant hemodialysis, donor blood group B, and recipient gender in post-transplant 
BKV infection. Two mismatches of HLA-C vs. no mismatch provided a protective effect in 
univariable analysis. We forced recipient age (p=0.08 in univariable analysis) in all 
multivariable models.  
Since patients have combinations of different HLA molecules, interaction between HLA 
variables was expected. We initially calculated Pearson correlation coefficients to examine 
interactions between variables. The result of these tests showed a significant interaction 
between HLA B35 and Cw4 (p=0.0001). Both variables had significant associations with 
BKV infection in univariable analysis. Considering the interaction between these two 
variables, we made a new variable of “B35/Cw4”(0=B35-/Cw4-, 1=B35+/Cw4- or B35-
/Cw4+ and 2=B35+/Cw4+). In univariable analysis, B35/Cw4 +/+ significantly increased the 
risk of BKV infection (HR: 3.2, CI 95%: 1.6-6.5).  
We did not include “donor blood group B vs. non-B” in the model despite significant 
association with BKV infection in univariable analysis. This was because the non-B group 
included heterogeneous patients with different risks of rejection and graft loss (blood group 
A, AB and O).  
 
 
52 
 
 
Cox proportional hazard model 
 
Table 6 provides our findings in Cox proportional hazard regression analysis in detail. 
Male gender (HR: 2.95, CI 95%: 1.3-6.6), pre-transplant HD vs. non-HD (HR: 3.04, CI 95%: 
1.4-6.8), HLA-A1 (HR: 3.06, CI 95%: 1.5-6.2), HLA B35/Cw4 +/+ (HR: 4.6, CI 95%: 2.1-
10.1) significantly increased the risk of BKV infection. In this model, there was a 
quantitative association between recipient age and BKV infection (HR: 1.04, CI 95%: 1.01-
1.06). Two HLA mismatches of HLA-C provided a protective effect in this time-dependent 
analysis (HR one mismatch: 1.2, CI 95%: 0.4-3.3, HR two mismatch: 0.3, CI 95% : 0.1-0.98). 
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Table 6: Cox proportional hazard analysis  
 
  
 
Variables Sig
. 
HR 95.0% CI for HR 
Lower Upper 
Gender male    .008 2.95 1.32 6.57 
Pre-transplant chronic hemodialysis    .006 3.04 1.37 6.77 
HLAB35/Cw4Ω    .001    
HLAB35/Cw4 (+/- or -/+)    .758 1.22 .35 4.22 
HLAB35/Cw4 (+/+)    .000 4.63 2.12 10.14 
HLA A1    .002 3.06 1.51 6.17 
HLA C mismatch    .001    
HLA C one mismatch    .749 1.18 .42 3.31 
HLA C Two mismatch    .046 .32 .107 .98 
Recipient age (per year)    .006 1.04 1.01 1.06 
 
Ω Having either HLA B35 or HLA Cw4:  
-/-: the recipient had none of these two HLAs (reference in the analysis) 
+/- or -/+: the recipient had either one of these two HLAs 
+/+: the recipient had both HLAs 
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Discussion 
In this cohort, 175 renal allograft recipients were included. We continued one-year of 
follow-up after transplantation. The frequency of BKV infection in the first year after 
transplantation affects almost one quarter of patients (23%). BKV infection in our cohort 
was more frequent than previous reports (24,25,26)  but was similar to a recent report by 
Hirsch et al(27). Serial post-transplantation screening showed 50% of BKV infections 
occurred in the first 100 days and 75% in the first 170 days after transplantation (IQR 25%-
75%: 62-170 days). Based on Organ Procurement and Transplantation Network (OPTN) 
database with two- year follow up, 3.45% of renal transplant recipients in the United States 
required treatment for BKV infection. This frequency increased to 6.6% at 60 months(22). 
OPTN data was limited to patients who required treatment for BKV infection and not 
necessarily diagnosis of BK viremia. Considering the frequency of BK viremia in our data, it 
appears post-transplant BKV infection is a considerable problem in London, Ontario 
affecting approximately one fourth of renal transplant recipients. The reason for this high 
frequency of BKV infection is unclear to the authors.  This frequency of BK infection could 
be due to using highly sensitive diagnostic tests and a rigorous screening protocol. However, 
the molecular PCR test that we use in London is similar to other transplant centers in 
Canada. Further studies are needed to determine the reason(s) for such a frequency of BKV 
infection at London Health Science Centre.  
Although a recent study suggested BK viremia could occur independent of recipient 
characteristics(28), we found a significant association between recipient age and post-
transplant BKV infection in Cox proportional hazard model. Since cell mediated immunity is 
affected by age, this finding does not appear to be unexpected.  
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Additionally, in patients who received an organ from living donors, the median 
donor age was significantly higher in recipients with BKV infection. It has been shown that 
BK virus infection preferentially affects older recipients (29). It was also shown the 
frequency of BK viruria gradually increases with age even in immunocompetent 
patients(30). As well, the frequency of BKV infection in pediatric renal transplant recipients 
appears to be considerably lower than adult patients(31). All these data support the 
association between age and BKV infection. We hope further studies can provide risk 
stratification based on age of the donors and recipients. 
In this study, cold ischemia time and allograft rejection were not significantly associated 
with BKV infection. This finding supports similar data published by Priftakis et al(32). On 
the other hand, Dharnidharka et al(22) showed acute rejection in the first 6 months after 
transplantation may increase the risk of BKV infection. However, the authors identified a 
high frequency of HLA mismatch in that study and they believed the effect of rejection could 
be due to considerable frequency of HLA mismatch in patients with BKV infection. 
Although reducing immunosuppression after the diagnosis of BKV infection increases the 
risk of rejection, there is no clear data to show a reverse association suggesting allograft 
rejection is a risk factor for BKV infection or PyVAN.  
It has been shown that receiving tacrolimus increases the risk of BKV infection 
compared by cyclosporine(25). All patients in this cohort received tacrolimus and hence we 
were not able to compare the effect of tacrolimus with other CNIs. We were interested in 
demonstrating a dose dependent effect of tacrolimus on BKV infection. However, our data 
showed no quantitative association between tacrolimus serum level and BKV infection.  
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We were not able to determine area under curve (AUC) and maximal 
concentration (C max) of the medication to show the magnitude of exposure. We believe 
further pharmacokinetic studies are required to investigate the quantitative association 
between immunosuppression and BKV infection.  
In our study, HLA-A1 was significantly associated with post-transplant BKV infection. 
HLA-A1 has been recently shown to be associated with other post-transplant viral infections 
such as EBV related lymphoma (33), HSV(34), and CMV (35) infection. In addition, we 
found B35 and Cw4 increase the risk of BKV infection following renal transplantation. Due 
to an interaction between B35 and Cw4 in statistical analysis, we made a combined variable 
of B35/Cw4. Interestingly, we found a significant risk of BKV infection in recipients who 
have both HLA B35 and Cw4 (B35/Cw4 +/+). The role of HLA-B35 has been recently 
demonstrated in other viral diseases and specifically HIV infection(36,37). It appears HLA-
B35 increases the susceptibility to BKV infection as well. This HLA seems to be frequent in 
the Canadian population(38). On the other hand, HLA-Cw4 has been previously shown to be 
associated with autoimmune diseases(38,39). The association of HLA A1, B35 and Cw4 
remained significant in the Cox proportional hazard model. Further studies are required to 
determine the roles of these HLA variables in BKV infection. 
A higher frequency of HLA mismatch has been identified as a risk factor for BKV 
infection in either retrospective or prospective studies(40,18). In our study, HLA mismatch 
was not associated with post-transplant BKV infection. Our finding is similar to some other 
studies that did not show HLA mismatching as a risk factor for BKV infection(41,42,11). 
The protective effect of mismatching of two HLA-C which was found in Cox proportional 
hazard model does not seem biologically plausible.  
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Our study showed the frequency of BKV infection in patients who received rATG 
was not significantly different from patients who did not receive this medication. This 
finding was similar to OPTN data which showed a non-significant effect of induction with 
rATG(44). The maintenance immunosuppressive protocol was similar for all renal allograft 
recipients during this cohort. Thus, we were not able to compare the effects of 
immunosuppressive regimens. This is one of the limitations of this study.  
To our knowledge, this is the first study that compared the baseline risk of BKV 
infection between hemodialysis (HD) and peritoneal dialysis (PD) patients. Mitterhofer et al 
showed a low frequency of BKV infection in PD patients in a descriptive study(45). In our 
study, the risk of BKV infection in HD patients was significantly higher than PD patients in 
univariable analysis. In survival analysis, we showed different survival function of the 
outcome of BKV infection considering pretransplant PD vs. HD. Finally, the Cox 
proportional hazard model showed the risk of BKV infection is significantly higher in HD 
patients. To our knowledge, this is the first prospective study that showed significantly 
different baseline risk of BKV infection between HD and PD patients. Other investigators 
have shown a difference between HD and PD patients in terms of the function of the cell 
mediated immune system(46). This discrepancy may explain why HD patients are at a higher 
risk of BKV infection compared to PD patients. The process of hemodialysis seems to be 
associated with chronic activation of the immune system causing a chronic inflammatory 
response. The causes and consequences of hypercytokinemia in HD patients remains 
unknown(47). Further studies with a specific focus on chronic inflammatory response and 
function of cell mediated immunity in uremic patients may explain their vulnerability to 
BKV infection.  
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CHAPTER 4: GENERAL DISCUSSION AND CONCLUSION 
 
In this cohort study, we evaluated the roles of different variables that may increase the 
risk of BKV infection and PyVAN in renal transplant recipients using univariable, 
multivariable and time-dependent analyses.  
Our objective was to determine the risk factors for BKV infection (presumptive 
polyomavirus associated nephropathy, PyVAN) in renal allograft recipients. We believe the 
age of the recipient and recipient gender are two important variables that should be 
considered in risk stratification and screening strategies. The effects of these two variables 
have been demonstrated in previous studies(1,2). It was also assumed a sexually transmitted 
trigger for reactivation of BK disease (3, 4). Our data may support such a hypothesis. 
In addition to examining many variables that were previously identified, we also 
analyzed potential differences in risk associated with pre-transplantation dialysis modality, 
HD versus PD. PD and HD patients do not appear to have an equal baseline risk for BK 
virus infection at the time of transplantation. Chronic renal failure is accompanied by 
different immunologic abnormalities of innate and acquired immunity(5). These 
abnormalities include lymphopenia, altered percentage values of CD3+, CD3+/ 4+, CD19+ 
subpopulations and increased percentages of natural killer cells(6). Soluble IL-2 receptors 
are usually elevated in patients with ESRD. However, this level is considerably higher in PD 
patients rather than HD(7). HD patients have a significantly lower percentage of CD3-
positive cells than PD patients(7). This baseline characteristic of HD patients may cause 
more replication of BKV in their urothelial cells before transplantation. 
The process of apoptosis also seems less affected by PD than HD. It has been shown 
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that FAS expression is considerably higher in PD than in HD patients(8). The pattern 
of cytokine production by CD4-positive cells shows a significantly higher percentage of a 
Th1-type cytokine production in HD patients and Th2-type cytokine secretion in PD 
patients(9). This dissimilarity of immune system function between HD and PD patients may 
explain their different baseline risks of BKV infection at the time of transplantation. We 
believe further studies should focus on dysfunction of the immune system in uremic patients 
to explain the protective effect of PD vs. HD. 
We believe our finding related to the association between HLA-B35/ Cw4 and BK virus 
infection may suggest the role of killer cell immunoglobulin-like killer receptors (KIR). 
Such an association has been shown in other infectious diseases such as 
tuberculosis(10,11,12,13). KIR is responsible for checking the existence of MHC class I 
molecules, which function as their ligands. Although KIR receptors were previously 
recognized as specific for NK cells, currently these receptors are known to also present on T 
cells(14). Genetics of KIR molecules is very complex and that creates great variability. 
Additionally, some KIR are known to recognize HLA-A, HLA-B or HLA-C molecules(15). 
This makes a huge diversity of reactions, depending on the presence or absence of given KIR 
and their ligands, and therefore different susceptibility to BK virus infection. The interaction 
that we found in this study between HLA-B35 and HLA-C4 strongly suggests a probable 
role of KIR. We believe further studies are required to investigate the role of KIR in post-
transplant BKV infection.   
There are a number of potential limitations that could be associated with our study as an 
observational research. These limitations did not necessarily exist in this project but should 
be considered as potential issues. 
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An important one relates to my role as the observer while I was involved in the 
process of diagnosis and treatment of BKV infection. It was not possible to blind (i.e., keep 
the exposure status of the study participant unknown) the research team who were assessing 
the study outcome. Although we did our best to follow the protocol, knowing the exposure 
status of the study participant (PD vs HD) might have influenced the assessment of the 
outcome. 
Secondly, although we followed LHSC protocol for diagnosis of BKV infection in renal 
transplant recipients, it is possible that some patients more frequently performed the 
diagnosis tests. On the other hand, it is also possible that the diagnosis of BKV infection was 
delayed in some patients. This is specifically true for some patients who did not attend in the 
clinic in regular intervals.  
As an observational study, the existence of alternative explanations for study results due 
to confounding was carefully considered. To our knowledge, other than transplantation, no 
alternative explanation for BKV infection has been introduced in renal allograft recipients. 
The other limitation of observational studies is loss to follow-up. No patient in this study 
discontinued follow-up in the first year after transplantation. According to our protocol, 
recipients who were supposed to continue post-transplant follow-up in other medical centers 
were excluded.  
It is important to consider that our study was an explanatory research. Further studies 
are required to determine the roles of independent variables such as HD vs PD to predict the 
outcome of BKV infection in renal transplant recipients.  
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APPENDICES 
Appendix A: Summary of study methodology 
1. Type of study 
Single group cohort 
2. Data collection method 
We routinely collected the demographic data of the donors and the recipients. Dr Q Xu 
kindly provided the HLA data. These laboratory data were related to both donors and 
recipients in detail. As a result, we regularly collected all background information related to 
the renal allograft recipients and the donors. 
Inpatient Transplant Infectious Diseases consolation was routinely done after renal 
transplantation. We subsequently arranged follow-up visits at Transplant Infectious Diseases 
and Nephrology clinics at LHSC. In each visit, we reviewed symptoms, performed physical 
examination and monitored allograft function. We regularly performed laboratory tests to 
monitor serum electrolytes and tacrolimus levels.  
Our routine BKV screening protocol at LHSC includes BKV-PCR on plasma every 1-3 
months in the first 2 years after transplantation and subsequently every year until the end of 
the 5th post-transplant year. Our protocol also includes BKV-PCR in patients with allograft 
dysfunction or patients who require allograft biopsy. Histopathologic assessment for BKV is 
routinely included in all renal allograft biopsies. In case of detectable viremia, we regularly 
monitored BKV viral load and allograft function.  
We implemented regular screening strategy for all renal allograft recipients in June 
2012. As a routine, I received a copy of all plasma BK virus PCR results during this cohort. 
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In case of a positive result, we informed the patient and continued active follow-up.  
All data were transferred to an Excel spreadsheet.  
3. Inclusion Criteria 
1. Age ≥ 18 years 
2. Renal or renal/pancreas transplantation from living or deceased donors 
3. Receiving renal allograft at London Health Sciences Center (LHSC) 
4. Patient agrees to continue follow up at LHSC 
4. Exclusion Criteria 
1. Pediatric renal transplant patients 
2. Hematopoietic stem cell transplant patients 
3. Patients who receive renal allograft in other transplantation centers and continued 
post-transplantation follow-up at LHSC 
4. Patients who received allografts other than kidney or kidney-pancreas 
transplantation 
5. Polyomavirus (BK virus) PCR 
 
DNA extraction, using 400 µl of plasma, was performed on the MagNA Pure Compact 
instrument (Roche Diagnostics, Indianapolis, IN) with the MagNA Pure Total Nucleic Acid 
Isolation Kit I (Roche); samples were eluted in 50 µl.  The RealStar® BKV PCR (Altona 
Diagnostics, Kit 1.2) assay was performed on a Lightcycler 2.0 instrument (Roche) with BK 
viral load reported in copies/ml based on the provided standards. The RealStar®BKV PCR 
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Kit 1.2 is an in vitro diagnostic assay, based on real-time PCR, for the diagnosis of 
BKV infection and quantification of BKV DNA 
6. Statistical Software 
We used IBM SPSS Statistics version 24 (2015) for data analysis.  
7. Data analysis 
I. Categorical variables:  Absolute and relative frequencies, cumulative percent 
II. Quantitative variables: Mean, median, standard deviation, variance, mode, 
skewness, range, IQR 
III. Analytic analysis: chi-square test, Fisher’s exact test, cox proportional hazard 
regression, logistic regression, Mann-Whitney test 
8. Multivariate analysis 
We provided the results of Cox proportional hazard analysis which is a time-dependent 
test in Chapter 3. The following table demonstrates our findings of multivariate logistic 
regression test in detail. All variables that had associations with BK virus infection in 
univariate analyses (p<0.1) were included in this model. Despite Cox regression model, the 
logistic regression analysis is not time-dependent.  
9. Sample size, type I and type II errors: 
 
The desired power was 0.8 (type II error, ß=0.2). Considering the confidence level of 0.95 
and the expected incidence of 0.15 in this cohort, the calculated sample size was 114.  
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Table 7- Logistic regression analysis 
 
 
Variable 
Sig. Odds 
ratio 
95% C.I. for OR 
Lower Upper 
 
Gender   .012 3.57 1.32 9.68 
HLAB35/Cw4   .004    
HLAB35/Cw4 (+/-, -/+)   .870 1.14 .24 5.44 
HLAB35/Cw4(+/+)    .001 6.29 2.09 18.98 
HLA-A1    .012 3.10 1.28 7.50 
HD vs Non-HD    .010 3.59 1.35 9.51 
Locus Cw MMŒ    .007    
Locus Cw MM(1)    .681 1.30 .37 4.56 
Locus Cw MM(2)    .077 .30 .08 1.14 
Recipient age    .014 1.04 1.01 1.07 
Constant      .0001 .004   
 
Ω Having either HLA B35 or HLA Cw4:  
-/-: the recipient had none of these two HLAs (reference in the analysis) 
+/- or -/+: the recipient had either one of these two HLAs 
+/+: the recipient had both HLAs 
Œ MM: mismatch 
MM(1): one mismatch 
MM(2): two mismatches 
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Appendix B  
REB approval 
ROMEO - Researcher Portal General Info  
File No: 105559 Title: BK virus infection in the first year after renal transplantation in 
patients who were on hemodialysis vs. peritoneal dialysis before transplantation Start Date: 
19/08/2014 End Date: 19/08/2017  
Keywords: BK virus, renal, transplantation, hemodialysis, peritoneal dialysis  
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
 
 
 
 
 
 
79 
 
 
Curriculum Vitae 
 
Name:   SEYED M. HOSSEINI-MOGHADDAM 
 
Post-secondary  Babol University of Medical Sciences 
Education and  Babol, Iran 
Degrees:   1988-1994 MD 
 
Tehran University of Medical Sciences  
Tehran, Iran 
1994-1996 MSc, Public Health 
 
Shahid Beheshti University of Medical Sciences 
Tehran, Iran 
1996-2000, Specialty of Infectious Diseases and Tropical Medicine  
 
University of Toronto 
Toronto, Canada 
2009-2011, General Internal Medicine 
 
University of Toronto, 
Toronto,Canada 
2011-2012, Transplant Infectious Diseases 
 
 
Honors and               Canadian National Transplant Research Program,  
Awards:   2015-2016 
 
Related Work  Director of Transplant Infectious Diseases 
Experience   London, Canada 
2014-Now 
 
 
PUBLICATIONS 
1. Hosseini-Moghaddam SM, Alhomayeed B, Soliman N, et al. Primary Epstein-Barr virus 
infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal 
allograft recipients: a prospective cohort study. Transpl Inf Dis, 2016 18 (3);423-30 
2. Hosseini-Moghaddam SM, Chaparro C, et al. The Effectiveness of Culture-Directed 
Preemptive Anti-Aspergillus Treatment in Lung Transplant Recipients at One Year after Transplant. 
Transplantation. 2015 99(11);2387-93 
3. Bhaskaran A, Hosseini-Moghaddam SM, et al. Mold infections in lung transplant 
recipients. Seminars in Respiratory and Critical Care Medicine, 2013; 34 (3): 371-9. 
80 
 
 
4. Hosseini-Moghaddam SM, Keyvani H, et al. The frequency of HHV-8 infection in 
otherwise healthy blood donors as well as renal allograft recipients living in Iran. Arch Iran Med, 
2013 Jul 1; 16 (7): 376-9 
5. Minnema BJ, Husain S, Mazzulli T, Hosseini-Moghaddam SM, et al. Clinical 
characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients 
with hematologic malignancies: a retrospective cohort study. Leuk Lymphoma, 2013 Jun 1; 54 (6): 
1250-5 
6. Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole 
hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transpl, 2012; 12 (7): 1929-35 
7. Hosseini-Moghaddam SM, Soleimanirahbar A, Mazzulli T, et al. Post renal 
transplantation Kaposi’s sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical 
aspects, and therapy. Transpl Infect Dis. 2012; 14 (4): 338-45 
8. Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for voriconazole 
hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant. 2012; 12 (7): 1929-35 
9. Hosseini-Moghaddam SM, Rotstein C, Husain S. Effects of the intensity of 
immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. 
Am J Transplant. 2011; 11 (2): 407 
10. Hosseini-Moghaddam SM. Hepatitis E virus and renal transplantation. Hepat Mon. 2011; 
11 (8): 599-600 
11. Hosseini-Moghaddam SM, Zarei A, Alavian SM, Mansouri M. Hepatitis E virus 
infection: a general review with a focus on hemodialysis and kidney transplant patients. Am J 
Nephrol. 2010; 31 (5): 398-407 
12. Hosseini-Moghaddam SM, Husain S. Fungi and molds following lung transplantation. 
Semin Respir Crit Care Med. 2010; 31 (2): 222-33 
13. Golestan B, Hosseini-Moghaddam SM, Nafar M, Rennolls K, Mohammad K. An 
estimation of the chronic rejection of kidney transplant using an eternal Weibull regression: a 
historical cohort study. Arch Iran Med, 2009 Jul 1; 12 (4): 341-6 
14. Basiri A, Shakhssalim N, Hosseini-Moghddam SM, Parvaneh MJ, Azadvari M. Renal 
transplant in patients with spinal cord injuries. Exp Clin Transpl, 2009; 7 (1): 28-32 
15. SM Hosseini-Moghaddam, SHamideh Mousavi , SM Alavian. Is SEN virus a major 
concern in hemodialysis and transplantation? Journal of Hepatitis Monthly, 2009; 9 (1): 50-59 
16. Golestan B, Hosseini-Moghaddam SM, Nafar M, et al. An estimation of the chronic 
rejection of kidney transplant using an eternal Weibull regression: a historical cohort study. Arch Iran 
Med. 2009; 12 (4): 341-6 
17. Hosseini-Moghaddam SM, Alavian SM. Hepatitis C and renal transplantation: a review 
on historical aspects and current issues. Rev Med Virol, 2008 Nov 1; 18 (6): 375-86 
18. Basiri A, Hosseini-Moghaddam SM, Simforoosh N, et al. The risk factors and laboratory 
diagnostics for post renal transplant tuberculosis: a case-control, country-wide study on definitive 
cases. Tanaffos,2006 5(17):19-246 
19. Hosseini- Moghaddam SM, Iran Pour E. Adeforvir as a novel drug for the treatment of 
chronic hepatitis B in patients with End- Stage renal disease and kidney recipients. Hepatitis 
Monthly, 2006 8(2):135-139 
81 
 
 
20. Basiri A, Hosseini-Moghaddam SM, Simforoosh N, et al. The risk factors and 
laboratory diagnostics for post renal transplant tuberculosis: a case-control, country-wide study on 
definitive cases. Transpl Infect Dis. 2008; 10 (4): 231-5 
21. Basiri A, Simforoosh N, Heidari M, Hosseini-Moghaddam SM. Laparoscopic v open 
donor nephrectomy for pediatric kidney recipients: preliminary report of a randomized controlled 
trial. J Endourol, 2007 Sep 1; 21 (9): 1033-6  
22. Amirzargar M, Yavangi M, Basiri A, et al. Genetic association of interleukin-4, interleukin-
10, and transforming growth factor-beta gene polymorphism with allograft function in renal 
transplant patients. Transplant Proc, 2007; 39 (4): 954-7 
23. Basiri A, Otukesh H, Hosseini-Moghaddam SM, Ghazi-Moghaddam B, Haidari M, 
Sharifian M, Razzaghi Z. Slow graft function after pediatric renal transplantation from volunteer live 
donors. Pediatr Transplant. 2007; 11 (5): 477-80 
24. Simforoosh N, Basiri A, Shakhssalim N, Ziaee SA, Tabibi A, Hosseini-Moghaddam SM. 
Effect of warm ischemia on graft outcome in laparoscopic donor nephrectomy. J Endourol, 2006; 20 
(11): 895-8 
25. Basiri A, Hoseini Moghaddam SM, Simsoroosh N, et al.. Risk Factors and Laboratory  
Diagnosis for Post Renal Transplant Tuberculosis : A Case -Control, Country-Wide Study on 
Definitive Cases. Tanaffos, 2006 Jul 1; 5(17): 19-24, Co- 
26. Basiri A, Otookesh H, Simforoosh N, Hosseini R, Hosseini-Moghaddam SM, Sharifian 
M. Does pre-transplantation antireflux surgery eliminate post-renal transplantation pyelonephritis in 
children? J Urol. 2006; 175 (4): 1490-2 
27. Basiri A, Nikoobakht MR, Simforoosh N, Hosseini Moghaddam SM. Ureteroscopic 
management of urological complications after renal transplantation. Scand J Urol Nephrol. 2006; 40 
(1): 53-6 
28. Basiri A, Hosseini-Moghaddam SM, Simforoosh N, et al. Preliminary report of a 
nationwide case-control study for identifying risk factors of tuberculosis following renal 
transplantation. Transplant Proc, 2005 Sep 1; 37 (7): 3041-4. 
29. Firoozan A, Hosseini Moghaddam SM, et al. Outcome of Kaposi’s sarcoma and graft 
following discontinuation of immunosuppressive drugs in renal transplant recipients. Transplant 
Proc. 2005; 37 (7): 3061-4 
30. Simforoosh N, Basiri A, Tabibi A, Shakhssalim N, Hosseini Moghaddam SM. Comparison 
of laparoscopic and open donor nephrectomy: a randomized controlled trial. BJU Int. 2005; 95 (6): 
851-5 
31. Basiri A, Simforoosh N, Khoddam R, Hosseini -Moghaddam SM, et al. A comparison of 
augmentation cystoplasty before and after renal transplantation with the control group. Urol J, 2004 
Jan; 1 (1): 45-8 
32. Basiri A, Simforoosh N, Nikoobakht M, Hosseini-Moghaddam SM. The role of 
ureteroscopy in the treatment of renal transplantation complications. Urol J, 2004 Jan; 1 (1): 27-31 
33. Poorrezagholi F, Einollahi B, Firoozan A, Nafar M, Yadegari H, Hosseini-Moghaddam 
SM, et al. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation. 
Transplant Proc, 2003 Nov 1; 35 (7): 2735-6,  
34. Basiri A, Ziaee SA, Hosseini- Moghaddam SM, et al. Laparoscopic living donor 
nephrectomy in a center with limited laparoscopic experience. Transplant Proc, 2003 Nov 1; 35 (7): 
2549-50 
82 
 
 
35. Simforoosh N, Bassiri A, Ziaee SA, Tabibi A, Salim NS, Pourrezagholi F, Hosseini-
Moghaddam SM, et al. Laparoscopic versus open live donor nephrectomy: the first randomized 
clinical trial. Transplant Proc, 2003 Nov 1; 35 (7): 2553-4 
36. Simforoosh N, Basiri A, Pourrezagholi F, Einolahi B, Firouzan A, Moghaddam MM, 
Nourbala MH, Hajarizadeh B, Pourfarziani V, Lessanpezeshki M, Nafar M, Khatami MR, Hosseini-
Moghaddam SM, Farhangi S. Is preemptive renal transplantation preferred? Transplant Proc, 2003 
Nov 1; 35 (7): 2598-601 
37. Basiri A, Hosseini Moghaddam S, Khoddam R. Augmentation cystoplasty before and after 
renal transplantation: long-term results. Transplantation Proceedings 2002; 34, Issue 6, 2106-2108.  
Book Chapter / Review Article 
1. S Husain, SM Hosseini-Moghaddam. Management of infections in Lung, Heart-Lung and 
Heart Transplant Recipients. The American Society of Transplantation Handbook of Transplantation 
Infections, WILEY-BLACKWELL, 2012, Part1, Chapter 11, 25.  
2. SM Hosseini-Moghaddam, S Husain. Nocardia. Infection in organ transplant recipients. 
Antimicrobial therapy the ultimate reference. Pittsburgh (United States); 2012. Antimicrobial therapy 
the ultimate reference. Infectious diseases and antimicrobial agents. www. antimicrobe.org - 
Pittsburgh, USA, 2012.  
